<DOC>
	<DOCNO>NCT02647359</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-masked , placebo-controlled study ataluren patient aniridia cause nonsense mutation . Patients receive mask study drug 48 week follow open-label ataluren another 48 week . Safety efficacy assess .</brief_summary>
	<brief_title>Study Ataluren Patients With Aniridia</brief_title>
	<detailed_description />
	<mesh_term>Aniridia</mesh_term>
	<criteria>Age ≥2 year Body weight ≥12 kg Documentation presence nonsense mutation 1 allele PAX6 gene Clinical diagnosis aniridia 20/200 bad visual acuity well eye best correction . Subjects monocular . Subjects history complicate ocular surgery</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>